Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Review Article

Discovery and Development of the Oral Complement Factor D Inhibitor Danicopan (ACH-4471)

Author(s): Jason A. Wiles, Manuel D. Galvan, Steven D. Podos, Michael Geffner and Mingjun Huang*

Volume 27, Issue 25, 2020

Page: [4165 - 4180] Pages: 16

DOI: 10.2174/0929867326666191001130342

Price: $65

Abstract

Complement plays a vital role in our innate immune defense against invasive microorganisms. Excessive complement activation or insufficient control of activation on host cells, however, is associated with several chronic disorders. Essential to the activation and amplification of the Alternative Pathway (AP) of complement, Complement Factor D (CFD) is a specific serine protease that cleaves its unique substrate, Complement Factor B (CFB) in complex with an activated form of complement component 3 (C3), to generate the AP C3 convertases C3(H2O)Bb and C3bBb. These convertases comprise a central component in eliciting effector responses following AP activation, and they also enable a powerful amplification loop for both the Classical Pathway (CP) and Lectin Pathway (LP) of complement. Because CFD is not required for the activation of either the CP or LP, selective CFD inhibition presents a favorable therapeutic approach to modulating complement activity that leaves intact the effector functions following CP and LP activation and thus poses a lower risk of bacterial infection than other complement-directed approaches. This review provides an update on inhibitors of CFD, which have evolved from irreversible small molecules that demonstrate poor selectivity to reversible small molecules and monoclonal antibodies that demonstrate exceptional selectivity and potency. The reversible small-molecule inhibitor danicopan (ACH-4471) has emerged recently as a promising therapeutic candidate. An overview of its discovery, preclinical pharmacology, Phase 1 clinical studies in healthy volunteers, and Phase 2 clinical studies in Paroxysmal Nocturnal Hemoglobinuria (PNH) patients is presented.

Keywords: Complement, alternative pathway, complement factor D, oral inhibitors, danicopan, ACH-4471, PNH.

« Previous Next »
[1]
Pekna, M.; Nilsson, L.; Nilsson-Ekdahl, K.; Nilsson, U.R.; Nilsson, B. Evidence for iC3 generation during cardiopulmonary bypass as the result of blood-gas interaction. Clin. Exp. Immunol., 1993, 91(3), 404-409.
[http://dx.doi.org/10.1111/j.1365-2249.1993.tb05916.x] [PMID: 8443963]
[2]
Harboe, M.; Garred, P.; Karlstrøm, E.; Lindstad, J.K.; Stahl, G.L.; Mollnes, T.E. The down-stream effects of mannaninduced lectin complement pathway activation depend quantitatively on alternative pathway amplification. Mol. Immunol., 2009, 47(2-3), 373-380.
[http://dx.doi.org/10.1016/j.molimm.2009.09.005] [PMID: 19800125]
[3]
Harboe, M.; Ulvund, G.; Vien, L.; Fung, M.; Mollnes, T.E. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin. Exp. Immunol., 2004, 138(3), 439-446.
[http://dx.doi.org/10.1111/j.1365-2249.2004.02627.x] [PMID: 15544620]
[4]
Podos, S.D.; Agarwal, A.; Huang, M.; Factor, D. Complement FactsBook, 2nd ed; LindaVersteeg-Buschman;Elsevier Science B: United-Kingdom, 2018, pp. 117-126.
[5]
Volanakis, J.E.; Narayana, S.V. Complement factor D, a novel serine protease. Protein Sci., 1996, 5(4), 553-564.
[http://dx.doi.org/10.1002/pro.5560050401] [PMID: 8845746]
[6]
Fearon, D.T.; Austen, K.F.; Ruddy, S. Properdin factor D: characterization of its active site and isolation of the precursor form. J. Exp. Med., 1974, 139(2), 355-366.
[http://dx.doi.org/10.1084/jem.139.2.355] [PMID: 4855753]
[7]
Cole, L.B.; Chu, N.; Kilpatrick, J.M.; Volanakis, J.E.; Narayana, S.V.; Babu, Y.S. Structure of diisopropyl fluorophosphate-inhibited factor D. Acta Crystallogr. D Biol. Crystallogr., 1997, 53(Pt 2), 143-150.
[http://dx.doi.org/10.1107/S0907444996012991] [PMID: 15299948]
[8]
Narayana, S.V.; Carson, M.; el-Kabbani, O.; Kilpatrick, J.M.; Moore, D.; Chen, X.; Bugg, C.E.; Volanakis, J.E.; DeLucas, L.J. Structure of human factor D. A complement system protein at 2.0 A resolution. J. Mol. Biol., 1994, 235(2), 695-708.
[http://dx.doi.org/10.1006/jmbi.1994.1021] [PMID: 8289289]
[9]
Kam, C.M.; Oglesby, T.J.; Pangburn, M.K.; Volanakis, J.E.; Powers, J.C. Substituted isocoumarins as inhibitors of complement serine proteases. J. Immunol., 1992, 149(1), 163-168.
[PMID: 1607651]
[10]
Jing, H.; Babu, Y.S.; Moore, D.; Kilpatrick, J.M.; Liu, X.Y.; Volanakis, J.E.; Narayana, S.V. Structures of native and complexed complement factor D: implications of the atypical His57 conformation and self-inhibitory loop in the regulation of specific serine protease activity. J. Mol. Biol., 1998, 282(5), 1061-1081.
[http://dx.doi.org/10.1006/jmbi.1998.2089] [PMID: 9753554]
[11]
Cole, L.B.; Kilpatrick, J.M.; Chu, N.; Babu, Y.S. Structure of 3,4-dichloroisocoumarin-inhibited factor D. Acta Crystallogr. D Biol. Crystallogr., 1998, 54(Pt 5), 711-717.
[http://dx.doi.org/10.1107/S0907444997010457] [PMID: 9757085]
[12]
Szalai, A.J.; Digerness, S.B.; Agrawal, A.; Kearney, J.F.; Bucy, R.P.; Niwas, S.; Kilpatrick, J.M.; Babu, Y.S.; Volanakis, J.E. The Arthus reaction in rodents: species-specific requirement of complement. J. Immunol., 2000, 164(1), 463-468.
[http://dx.doi.org/10.4049/jimmunol.164.1.463] [PMID: 10605043]
[13]
Fujii, S.; Hitomi, Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim. Biophys. Acta, 1981, 661(2), 342-345.
[http://dx.doi.org/10.1016/0005-2744(81)90023-1] [PMID: 6271224]
[14]
Ikari, N.; Sakai, Y.; Hitomi, Y.; Fujii, S. New synthetic inhibitor to the alternative complement pathway. Immunology, 1983, 49(4), 685-691.
[PMID: 6553561]
[15]
Tomioka, N.S.Y.; Itai, A. The refined crystal structure of the complex formed by bovine trypsin and p-guanidinobenzoate at 2.06 A resolution. FEBS Lett., 1989, 1, 153-155.
[http://dx.doi.org/10.1016/0014-5793(89)81638-2]
[16]
Narayana, S.V.B.Y.S.; Volanakis, J.E. Contemporary Immunology; Humana Press Inc.: Totowa, NJ, 2000.
[17]
Johnson, D.S.; Weerapana, E.; Cravatt, B.F. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. Future Med. Chem., 2010, 2(6), 949-964.
[http://dx.doi.org/10.4155/fmc.10.21] [PMID: 20640225]
[18]
Katschke, K.J., Jr; Wu, P.; Ganesan, R.; Kelley, R.F.; Mathieu, M.A.; Hass, P.E.; Murray, J.; Kirchhofer, D.; Wiesmann, C.; van Lookeren Campagne, M. Inhibiting alternative pathway complement activation by targeting the factor D exosite. J. Biol. Chem., 2012, 287(16), 12886-12892.
[http://dx.doi.org/10.1074/jbc.M112.345082] [PMID: 22362762]
[19]
Loyet, K.M.; Good, J.; Davancaze, T.; Sturgeon, L.; Wang, X.; Yang, J.; Le, K.N.; Wong, M.; Hass, P.E.; van Lookeren Campagne, M.; Haughney, P.C.; Morimoto, A.; Damico-Beyer, L.A.; DeForge, L.E. Complement inhibition in cynomolgus monkeys by anti-factor d antigen-binding fragment for the treatment of an advanced form of dry age-related macular degeneration. J. Pharmacol. Exp. Ther., 2014, 351(3), 527-537.
[http://dx.doi.org/10.1124/jpet.114.215921] [PMID: 25232192]
[20]
Roche Press Release. Available at:https://www.roche.com/media/store/releases/med-cor-2017-09-08b.htm (Accessed March 11, 2018).
[21]
Roche Development Pipeline Update. Available at:https://www.roche.com/dam/jcr:77aa35dc-feef-427b-b9e3-befd9e735d2e/en/irp180201-annex.pdf (Accessed March 11, 2018)
[22]
Rawlings, ND.; Salvesen, G. Handbook of proteolytic enzymes. In: Academic press, 3rd ed; , 2013; 135, pp. (2)2841-2848.
[23]
Forneris, F.; Ricklin, D.; Wu, J.; Tzekou, A.; Wallace, R.S.; Lambris, J.D.; Gros, P. Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science, 2010, 330(6012), 1816-1820.
[http://dx.doi.org/10.1126/science.1195821] [PMID: 21205667]
[24]
Pais, G.; Hashimoto, A.; Gadhachanda, V.R.; Wang, Q.; Chen, D.; Wang, X.; Agarwal, A.; Deshpande, M.; Phadke, A. Alkyne compounds for treatment of complement mediated disorders., W.O. 2015130784A1. 2015.
[25]
Wang, Q.; Gadhachanda, V.R.; Pais, G.; Hashimoto, A.; Chen, D.; Wang, X.; Agarwal, A.; Deshpande, M.; Phadke, A.; Wiles, J.A. Amide compounds for treatment of complement mediated disorders., W.O. 20015/130795A1. 2015.
[26]
Gadhachanda, V.R.; Hashimoto, A.; Pais, G.; Wang, Q.; Chen, D.; Wang, X.; Agarwal, A.; Deshpande, M.; Wiles, J. A.; Phadke, A. Amino compounds for treatment of complement mediated disorders, W.O. 2015130806A1. 2015.
[27]
Gadhachanda, V.R; Pais, G.; Hashimoto, A.; Wang, Q.; Chen, D.; Wang, X.; Agarwal, A.; Deshpande, M.; Phadke, A.; Wiles, J. A. Carbamate, ester, and ketone compounds for treatment of complement mediated disorders, W.O.2015130830A1. 2015.
[28]
Gadhachanda, V.R.; Wang, Q.; Pais, G.; Hashimoto, A.; Chen, D.; Wang, X.; Agarwal, A.; Deshpande, M.; Wiles, J. A.; Phadke, A. Aryl, heteroaryl, and heterocyclic compounds for treament of complement mediated disorders, W.O. 2015130838A1. 2015.
[29]
Wiles, J.A.; Hashimoto, A.; Gadhachanda, V.R.; Pais, G.; Wang, Q.; Chen, D.; Wang, X.; Agarwal, A.; Deshpande, M.; Phadke, A. Phosphonate compounds for treatment of complement medi-ated disorders., W.O. 2015130845A1. 2015.
[30]
Gadhachanda, V.R.; Pais, G.; Hashimoto, A.; Wang, Q.; Chen, D.; Wang, X.; Agarwal, A.; Deshpande, M.; Phadke, A.; Wiles, J. A. Ether Compounds for treatment of complement mediated disorders., W.O. 2015130842A2. 2015.
[31]
Phadke, A.; Wang, X.; Chen, D.; Hashimoto, A.; Gadhachanda, V.R.; Pais, G.; Wang, X.; Agarwal, A.; Deshpande, M.; Wiles, J. A. Compounds for treatment of complement mediated disorders.., W.O. 2015130854A12015.
[32]
Altmann, E.; Hommel, U.; Lorthiosis, E.L.J.; Maibaum, J.K.; Ostermann, N.; Quancard, J.; Randl, S.A.; Simic, O.; Vulpetti, A.; Rogel, O. Indole compounds or analogues thereof useful for the treat-ment of age-related macular degeneration (AMD)., W.O. 2012093101A1. 2012.
[33]
Altmann, E.; Hommel, U.; Lorthiosis, E.L.J.; Maibaum, J.K.; Termann, N.; Quancard, J.; Randl, S.A.; Vulpetti, A.; Rogel, O. Complement pathway modulators and uses thereof., W.O. 2014002051A2. 2014.
[34]
Flohr, S.; Hommel, U.; Lorthiosis, E.L.J.; Mabaum, J.K.; Ostermann, N.; Randl, S. A.; Vulpetti, A.; Quancard, J. Pyrrolidine derivatives and their use as complement pathway modulators., W.O. 2014002052A1,. 2014.
[35]
Altmann, E.; Hommel, U.; Lorthiosis, E.L.J.; Maibaum, J.K.; Ostermann, N.; Randl, S.A.; Vulpetti, A.; Rogel, O. Pyrrolidine derivatives and their use as complement pathway modulators., W.O. 2014002053A1,. 2014.
[36]
Altmann, E.; Hommel, U.; Lorthiosis, E.L.J.; Maibaum, J.K.; Ostermann, N.; Quancard, J.; Randl, S.A.; Vulpetti, A.; Rogel, O. Pyrrolidine derivatives and their use as complement pathway modulators., W.O. 2014002054A1. 2014.
[37]
Hommel, U.; Lorthiosis, E.L.J.; Maibaum, J.K.; Ostermann, N.; Randl, S.A.; Simic, O.; Vulpetti, A.; Rogel, O. Pyrrolidine derivatives and their use as complement pathway modulators, W.O. 2014002057A1. 2014.
[38]
Altmann, E.; Hommel, U.; Lorthiosis, E.L.J.; Maibaum, J.K.; Ostermann, N.; Quancard, J.; Randl, S.A.; Vulpetti, A.; Flohr, S.; Rogel, O. Complememt pathway modulators and uses thereof., W.O. 2014002058A2. 2014.
[39]
Towler, C.; Altman, E.; Hommel, U.; Lorthiosis, E.L.J.; Maibaum, J.K.; Ostermann, N.; Quancard, J.; Randl, S.A.; Simic, O.; Vulpetti, A. Cyrstalline forms of 1-(2- ((1R,3S,5R)-3-((R)-1-(3-chloro-2-fluorophenyl)ethyl) carbamolyl)- 2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1Hpyrazol[ 3,4-c]pyridine-3-carboxamide.., W.O. 20140020-59A1. 2014.
[40]
Towler, C.; Altmann, E.; Hommel, U.; Lorthiosis, E.L.J.; Maibaum, J.K.; Ostermann, N.; Quancard, J.; Randl, S.A.; Simic, O.; Vulpetti, A. Cyrstalline forms of L-(2- ((LR,3S,5R)-3-(2-Fluoro-3-trifluodomethoxy) phenyl_ carbamoyl) -2 azabicycle O [3.1.0] hexan-2-yl-oxoethyl) -5 - methyl-1H-pyrazolo [3,4-C] pyridine -3- carboxamide and salts thereof. W.O. 2014005150A1. 2014.
[41]
Maibaum, J.; Liao, S.M.; Vulpetti, A.; Ostermann, N.; Randl, S.; Rüdisser, S.; Lorthiois, E.; Erbel, P.; Kinzel, B.; Kolb, F.A.; Barbieri, S.; Wagner, J.; Durand, C.; Fettis, K.; Dussauge, S.; Hughes, N.; Delgado, O.; Hommel, U.; Gould, T.; Mac Sweeney, A.; Gerhartz, B.; Cumin, F.; Flohr, S.; Schubart, A.; Jaffee, B.; Harrison, R.; Risitano, A.M.; Eder, J.; Anderson, K. Small-molecule factor D inhibitors targeting the alternative complement pathway. Nat. Chem. Biol., 2016, 12(12), 1105-1110.
[http://dx.doi.org/10.1038/nchembio.2208] [PMID: 27775713]
[42]
Vulpetti, A.; Randl, S.; Rüdisser, S.; Ostermann, N.; Erbel, P.; Mac Sweeney, A.; Zoller, T.; Salem, B.; Gerhartz, B.; Cumin, F.; Hommel, U.; Dalvit, C.; Lorthiois, E.; Maibaum, J. Structure-based library design and fragment screening for the identification of reversible complement factor D protease inhibitors. J. Med. Chem., 2017, 60(5), 1946-1958.
[http://dx.doi.org/10.1021/acs.jmedchem.6b01684] [PMID: 28157311]
[43]
Hommel, U.; Lorthiosis, E.L.J.; Maibaum, J.K.; Ostermann, N.; Randl, S.A.; Vulpetti, A.; Rogel, O. Complement pathway modulators and used thereof., W.O. 2014009833A2. 2014.
[44]
Lorthiois, E.; Anderson, K.; Vulpetti, A.; Rogel, O.; Cumin, F.; Ostermann, N.; Steinbacher, S.; Mac Sweeney, A.; Delgado, O.; Liao, S.M.; Randl, S.; Rüdisser, S.; Dussauge, S.; Fettis, K.; Kieffer, L.; de Erkenez, A.; Yang, L.; Hartwieg, C.; Argikar, U.A.; La Bonte, L.R.; Newton, R.; Kansara, V.; Flohr, S.; Hommel, U.; Jaffee, B.; Maibaum, J. Discovery of highly potent and selective small-molecule reversible factor D inhibitors demonstrating alternative complement pathway inhibition in vivo. J. Med. Chem., 2017, 60(13), 5717-5735.
[http://dx.doi.org/10.1021/acs.jmedchem.7b00425] [PMID: 28621538]
[45]
Yuan, X.; Gavriilaki, E.; Thanassi, J.A.; Yang, G.; Baines, A.C.; Podos, S.D.; Huang, Y.; Huang, M.; Brodsky, R.A. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Haematologica, 2017, 102(3), 466-475.
[http://dx.doi.org/10.3324/haematol.2016.153312] [PMID: 27810992]
[46]
Konar, M.; Granoff, D.M. Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults. Blood, 2017, 130(7), 891-899.
[http://dx.doi.org/10.1182/blood-2017-05-781450] [PMID: 28630122]
[47]
Yang, C.Y.; Phillips, J.G.; Stuckey, J.A.; Bai, L.; Sun, H.; Delproposto, J.; Brown, W.C.; Chinnaswamy, K. Buried hydrogen bond interactions contribute to the high potency of complement factor D inhibitors. ACS Med. Chem. Lett., 2016, 7(12), 1092-1096.
[http://dx.doi.org/10.1021/acsmedchemlett.6b00299] [PMID: 27994744]
[48]
McDonald, A.; Qian, S. Therapeutic inhibitory compounds, W.O. 2017098328A2. 2017.
[49]
Kotian, P.L.; Babu, Y.S; Zhang, W.; Vogeti, L.; Wu, M.; Chintareddy, V.R.; Raman, K. Benzopyrazole compounds and analogues thereof., W.O. 2017136395A1. 2017.
[50]
McDonald, A; Qian, S. Therapeutic inhibitory compounds, W.O. 2018015818A2. 2018.
[51]
Belanger, D.B.; Flohr, S.; Gelin, C.F.; Jendza, K. Aminomethyl-biaryl derivatives complement factor D inhibi-tors and uses thereof.W.O. 2015009977A1. 2015.
[52]
Belanger, D.; Flohr, S.; Gelin, C.F.; Jendza, K.; Ji, N.; Karki, R.G.; Liu, D.; Lorthiois, E.L.J.; Mainolfi, N.; Powers, J.J.; Vulpetti, A. Amidomethyl-biaryl derivatives complement factor D inhibi-tors and uses thereof., W.O.2016088082A1. 2016.
[53]
McGeer, P.L.; Lee, M.; McGeer, E.G. Acetyl salicyclic acid dimers sythesis thereof, and uses there-of to prevent and treat complement-mediated disorders., W.O.2015070354A1,. 2015.
[54]
Lee, M.; Wathier, M.; Love, J.A.; McGeer, E.; McGeer, P.L. Inhibition of aberrant complement activation by a dimer of acetylsalicylic acid. Neurobiol. Aging, 2015, 36(10), 2748-2756.
[http://dx.doi.org/10.1016/j.neurobiolaging.2015.06.018] [PMID: 26248865]
[55]
Ellis-Pegler, R.; Schwabe, C.; Ajari, I.; Robison, H.; Sorensen, R.; Lahey, J.; Yang, W.; Huang, M.; Hui, J.; Kocinsky, H.; Geffner, M.; Apelian, D. An orally administered small molecule factor D inhibitor (ACH-4471) for treatment of PNH and complement diseases: preliminary phase 1 results in healthy volunteers. European Hematology Association 21st Congress, Copenhhagen, Abstract EHA-4145,, 2016, 101>-416.
[56]
Patel, D.; Thanassi, J.A.; Guangwei, Y.; Xuan, Y.; Brodsky, R.A.; Mingjun, H.; Podos, S.D. In vitro combination studies of ACH-4471 with eculizumab to assess a potential “Switch” treatment approach for paroxysmal nocturnal hemoglobinuria. American Society of Hematology 59th Annual Meeting and Exposition, Altanta,, GA2017.
[57]
Späth-Schwalbe, E.; Schrezenmeier, H.; Heimpel, S.H. [Paroxysmal nocturnal hemoglobinuria. Clinical experiences with 40 patients at one center over 25 years] Dtsch. Med. Wochenschr., 1995, 120(30), 1027-1033.
[PMID: 7628314]
[58]
Schubert, J.; Röth, A. Update on paroxysmal nocturnal haemoglobinuria: on the long way to understand the principles of the disease. Eur. J. Haematol., 2015, 94(6), 464-473.
[http://dx.doi.org/10.1111/ejh.12520] [PMID: 25702878]
[59]
Hill, A.; Rother, R.P.; Arnold, L.; Kelly, R.; Cullen, M.J.; Richards, S.J.; Hillmen, P. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Haematologica, 2010, 95(4), 567-573.
[http://dx.doi.org/10.3324/haematol.2009.007229] [PMID: 20145265]
[60]
Rondelli, T.; Risitano, A.M.; Peffault de Latour, R.; Sica, M.; Peruzzi, B.; Ricci, P.; Barcellini, W.; Iori, A.P.; Boschetti, C.; Valle, V.; Frémeaux-Bacchi, V.; De Angioletti, M.; Socie, G.; Luzzatto, L.; Notaro, R. Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria. Haematologica, 2014, 99(2), 262-266.
[http://dx.doi.org/10.3324/haematol.2013.090001] [PMID: 24038027]
[61]
Nishimura, J.; Yamamoto, M.; Hayashi, S.; Ohyashiki, K.; Ando, K.; Brodsky, A.L.; Noji, H.; Kitamura, K.; Eto, T.; Takahashi, T.; Masuko, M.; Matsumoto, T.; Wano, Y.; Shichishima, T.; Shibayama, H.; Hase, M.; Li, L.; Johnson, K.; Lazarowski, A.; Tamburini, P.; Inazawa, J.; Kinoshita, T.; Kanakura, Y. Genetic variants in C5 and poor response to eculizumab. N. Engl. J. Med., 2014, 370(7), 632-639.
[http://dx.doi.org/10.1056/NEJMoa1311084] [PMID: 24521109]
[62]
Achillion Press Release. Available at:http://ir.achillion.com/releasedetail.cfm?ReleaseID=1036547 (Accessed, March 31, 2018)
[63]
Figueroa, J.E.; Densen, P. Infectious diseases associated with complement deficiencies. Clin. Microbiol. Rev., 1991, 4(3), 359-395.
[http://dx.doi.org/10.1128/CMR.4.3.359] [PMID: 1889047]
[64]
Audemard-Verger, A.; Descloux, E.; Ponard, D.; Deroux, A.; Fantin, B.; Fieschi, C.; John, M.; Bouldouyre, A.; Karkowsi, L.; Moulis, G.; Auvinet, H.; Valla, F.; Lechiche, C.; Davido, B.; Martinot, M.; Biron, C.; Lucht, F.; Asseray, N.; Froissart, A.; Buzelé, R.; Perlat, A.; Boutboul, D.; Fremeaux-Bacchi, V.; Isnard, S.; Bienvenu, B. Infections revealing complement deficiency in adults: a French nationwide study enrolling 41 patients. Medicine (Baltimore), 2016, 95(19) e3548
[http://dx.doi.org/10.1097/MD.0000000000003548] [PMID: 27175654]
[65]
Figueroa, J.; Andreoni, J.; Densen, P. Complement deficiency states and meningococcal disease. Immunol. Res., 1993, 12(3), 295-311.
[http://dx.doi.org/10.1007/BF02918259] [PMID: 8288947]
[66]
Sng, C.C.T.; O’Byrne, S.; Prigozhin, D.M.; Bauer, M.R.; Harvey, J.C.; Ruhle, M.; Challis, B.G.; Lear, S.; Roberts, L.D.; Workman, S.; Janowitz, T.; Magiera, L.; Doffinger, R.; Buckland, M.S.; Jodrell, D.J.; Semple, R.K.; Wilson, T.J.; Modis, Y.; Thaventhiran, J.E.D. A type III complement factor D deficiency: Structural insights for inhibition of the alternative pathway. J. Allergy Clin. Immunol., 2018, 142(1), 311-314.e6.
[http://dx.doi.org/10.1016/j.jaci.2018.01.048] [PMID: 29522842]
[67]
Hiemstra, P.S.; Langeler, E.; Compier, B.; Keepers, Y.; Leijh, P.C.; van den Barselaar, M.T.; Overbosch, D.; Daha, M.R. Complete and partial deficiencies of complement factor D in a Dutch family. J. Clin. Invest., 1989, 84(6), 1957-1961.
[http://dx.doi.org/10.1172/JCI114384] [PMID: 2687330]
[68]
Weiss, S.J.; Ahmed, A.E.; Bonagura, V.R. Complement factor D deficiency in an infant first seen with pneumococcal neonatal sepsis. J. Allergy Clin. Immunol., 1998, 102(6 Pt 1), 1043-1044.
[http://dx.doi.org/10.1016/S0091-6749(98)70346-X] [PMID: 9847449]
[69]
Biesma, D.H.; Hannema, A.J.; van Velzen-Blad, H.; Mulder, L.; van Zwieten, R.; Kluijt, I.; Roos, D. A family with complement factor D deficiency. J. Clin. Invest., 2001, 108(2), 233-240.
[http://dx.doi.org/10.1172/JCI200112023] [PMID: 11457876]
[70]
Sprong, T.; Roos, D.; Weemaes, C.; Neeleman, C.; Geesing, C.L.; Mollnes, T.E.; van Deuren, M. Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections. Blood, 2006, 107(12), 4865-4870.
[http://dx.doi.org/10.1182/blood-2005-07-2820] [PMID: 16527897]
[71]
Kluin-Nelemans, H.C.; van Velzen-Blad, H.; van Helden, H.P.; Daha, M.R. Functional deficiency of complement factor D in a monozygous twin. Clin. Exp. Immunol., 1984, 58(3), 724-730.
[PMID: 6568950]
[72]
Rother, R.P.; Rollins, S.A.; Mojcik, C.F.; Brodsky, R.A.; Bell, L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat. Biotechnol., 2007, 25(11), 1256-1264.
[http://dx.doi.org/10.1038/nbt1344] [PMID: 17989688]
[73]
Zhao, Y.; Galvan, M.D.; Podos, S.D.; Thanassi, J.A.; Yang, G.; Patel, D.; Fabrycki, J.; Luu, A.; Yang, W.; Wiles, J.; Phadke, A.; Barrish, J.; Huang, M. Assessment of complement-mediated bactria killing and effect of a small molecule factor D on the killing in vitro. XXVI International Complement Workshop, Kanazawa, Japan2016, pp. 4-8.

Rights & Permissions Print Cite
Article Metrics
226
19
World Chagas Disease
© 2024 Bentham Science Publishers | Privacy Policy